ProJenX, founded in 2021 and headquartered in Nissequogue, New York, is a clinical-stage biotechnology company dedicated to developing novel small molecule therapeutics targeting motor neuron degenerative pathways. The company's core mission is to bring innovative treatments to patients suffering from neurodegenerative diseases, with a particular focus on Amyotrophic Lateral Sclerosis (ALS). ProJenX's flagship product, prosetin, is a first-in-class MAP4 kinase inhibitor designed to treat ALS.
ProJenX emerged from a long-standing collaboration between the ALS research nonprofit Project ALS and researchers at Columbia University. This partnership has been instrumental in advancing ProJenX's scientific endeavors. The company has garnered attention for its potential to revolutionize ALS treatment, marking significant progress in clinical trials. ProJenX's impact lies in its commitment to addressing unmet medical needs in neurodegenerative diseases, offering hope to patients and families affected by these debilitating conditions.
